We've Moved

We've moved! We no longer use this account. Please follow us at @Bioprocess365 to stay part of the conversation

[We've Moved @BioProduction]

We've moved! We no longer use this account - follow us at @Bioprocess365 for the latest news, content & events

[We've Moved @BioProduction]

What are the need-to-know #regulatory, #nonclinical & #clinical-specific characteristics of #microbiome products? Find out in a pre-conference workshop 'navigating the regulatory landscape for microbiome #therapeutics' with @VCLSsocial (27 March, Vienna): https://t.co/8i2ieefEnZ

[We've Moved @BioProduction]

Have you heard? We’re going through some changes. Our new account would love to meet you. Find us at @Bioprocess365

[We've Moved @BioProduction]

We’re moving! As of 10 June we’ll no longer be using this account. Follow @Bioprocess365 to keep getting updates

[We've Moved @BioProduction]

Dr. Victor Vinci, CSO @CookMedical told us why CMOs have a key role in the future of the #bioprocessing industry https://t.co/Ckxalf6AJR

[We've Moved @BioProduction]

Do CMOs act as a microcosm of the enormous change, excitement & complications in the wider #bioprocessing industry? https://t.co/57vnXNPc5B

[We've Moved @BioProduction]

"Traditional #pharma timelines need to be shorter & CMOs should have a part to play in that” https://t.co/mKhD0TZRoQ

[We've Moved @BioProduction]

WATCH: We spoke to Dr. Victor Vinci, CSO @CookMedical, about current CMO trends https://t.co/1A9u6Rz5jJ

[We've Moved @BioProduction]

WATCH: We spoke to Dr. Victor Vinci, CSO @CookMedical, about the trends, risks and tech in the CMO industry https://t.co/4yWPIFCLIa

[We've Moved @BioProduction]

The global cancer #immunotherapies market is expected to grow by over 15% each year until 2020 https://t.co/O7kRO7rQDT

[We've Moved @BioProduction]

Are there a raft of multi-billion dollar #biotech deals in the pipeline? https://t.co/lUO6R0reCF

[We've Moved @BioProduction]

“There are two main issues in the #bioproduction industry if you look at it from a 30,000 foot view" https://t.co/pdELeYft7O

[We've Moved @BioProduction]

Biopharma companies dominate @bcgperspectives's list of the world’s top value creators, @regeneron taking top spot https://t.co/ZDr9aZXduA

[We've Moved @BioProduction]

How has the FDA amended regulations on general biologic standards for first time since 1977? https://t.co/ewdZNpRl9e via @RAPSorg

[We've Moved @BioProduction]

6 reasons why the #biosimilars market is exp. to grow from $1.7b to $30b by 2020. @Frost_Sullivan for @BioProcessOL https://t.co/K9RMOTgkQD

[We've Moved @BioProduction]

Homology Medicines raises $43m funding with claim of "next generation #gene editing technology" https://t.co/cfALSjsdH1

[We've Moved @BioProduction]

Following approval in Japan for their insulin biosimilar, the future is looking bright for @Bioconlimited https://t.co/XF0URZ566z

[We've Moved @BioProduction]

.@GSK claim #gene therapy Strimvelis will be "significantly less" than $1m per patient https://t.co/8vSDrHbCfa via @FiercePharma

[We've Moved @BpiEurope]

David Radspinner, General Manager of @GEHealthcare Cell Culture, told us how they are improving production https://t.co/9KzXEWLWfw

[We've Moved @BioProduction]

New @IMSHealth report claims #biosimilars could save US & Europe $110billion by 2020. Read the full report here https://t.co/6pVyJVmQMj